<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36520">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631096</url>
  </required_header>
  <id_info>
    <org_study_id>ARB-001467-002</org_study_id>
    <nct_id>NCT02631096</nct_id>
  </id_info>
  <brief_title>Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</brief_title>
  <official_title>A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the
      safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of
      intravenous ARB-001467
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative
      subjects and one cohort of HBeAg-positive subjects. All subjects will be non-cirrhotic, with
      chronic hepatitis B virus (HBV) infection, and will have been receiving
      nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities to approximately 4 months after the start of the first infusion of study treatment</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ARB-001467 pharmacokinetics Cmax at multiple time points from baseline through Day 92</measure>
    <time_frame>Up to Day 92</time_frame>
    <description>To evaluate the maximum plasma concentration (Cmax) of multiple doses of ARB-001467 in subjects with chronic hepatitis B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARB-001467 pharmacokinetics Tmax at multiple time points from baseline through Day 92</measure>
    <time_frame>Up to Day 92</time_frame>
    <description>To evaluate the time to maximum plasma concentration (Tmax) of multiple doses of ARB-001467 in subjects with chronic hepatitis B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARB-001467 pharmacokinetics AUC0-t from the start of infusion to the last measurable concentration</measure>
    <time_frame>Up to Day 92</time_frame>
    <description>To evaluate the area under the plasma concentration-time curve (AUC0-t) from the start of infusion to the last measurable concentration of multiple doses of ARB-001467 in subjects with chronic hepatitis B</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at a dose level recommended by the ISC versus placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB-001467</intervention_name>
    <description>An IV infusion of ARB-001467 once a month for three months.</description>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An IV infusion of placebo once a month for three months.</description>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documented chronic HBV infection for ≥12 months prior to Screening Visit.

          -  Quantitative HBsAg ≥1000 IU/mL at the Screening Visit.

          -  Subjects currently receiving entecavir or tenofovir for ≥12 months and HBV DNA
             undetectable.

        Key Exclusion Criteria:

          -  Known co-infection with HIV, hepatitis C virus, or hepatitis D virus.

          -  Receiving or planning to receive systemic immunosuppressive medications during the
             study or ≤2 months prior to the first dose of study treatment.

          -  Receiving or planning to receive interferon during the study or ≤12 months prior to
             the first dose of study treatment.

          -  Significant immunosuppression from, but not limited to immunodeficiency conditions
             such as common variable hypogammaglobulinemia.

          -  Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months
             prior to the Screening Visit.

          -  Any known pre-existing medical or psychiatric condition that could interfere with the
             subject's ability to provide informed consent or participate in study conduct, or
             that may confound study findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Kowalski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Arbutus Biopharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Mendez, MD</last_name>
    <phone>+1-604-677-0248</phone>
    <email>pmendez@arbutusbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Murray</last_name>
    <phone>+1-604-419-3252</phone>
    <email>lmurray@arbutusbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Monash Health, Gastroenterology and Hepatology</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherryne Warner</last_name>
      <phone>61-03-9594-5516</phone>
      <email>sherryne.warner@monash.edu</email>
    </contact>
    <investigator>
      <last_name>William Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred, Gastroenterology and Hepatology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Lewis</last_name>
      <phone>61-03-9076-5276</phone>
      <email>paula.lewis@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Stuart Roberts, MD, MBBS, FRACP, FAASLD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Scott</last_name>
      <phone>1300-546327</phone>
      <email>contactus@linear.org.au</email>
    </contact>
    <investigator>
      <last_name>Wendy Cheng, MD, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hu</last_name>
      <phone>64-9373-3474</phone>
      <phone_ext>115</phone_ext>
      <email>Rebecca@clinicalstudies.co.nz</email>
    </contact>
    <investigator>
      <last_name>Edward Gane, MBChB, MD, FRACP, MNZM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital, Gastroenterology</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherryl Hayett</last_name>
      <phone>64(0)-2154-9659</phone>
      <email>Sherryl.Hayett@waikatodhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Frank Weilert, MBBCh, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 29, 2016</lastchanged_date>
  <firstreceived_date>December 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
